Abstract:Fms-like tyrosine kinase 3 (FLT3) is part of a family of receptor tyrosine kinases (RTKs), and a molecular therapeutic target of acute myeloid leukemia (AML). There are three FTL3 inhibitors, midostaurin, gilteritinib, and quizartinib have been approved for clinical treatment of AML. We have evaluated the inhibition of cell proliferation in vitro and antitumor activity in vivo of ETH-155008, a novel triple inhibitor of FLT3, Pim-3 and CDK4/6. ETH-155008 was found to have a strong inhibitory activity against key target enzymes (FLT3 IC50 at 0.5nM; Flt3 -Itd IC50 at 0.6 nM; CDK4/D1 IC50 at 0.8nM, CDK6/D1 IC50 at 1.4nM), which were more potent than the tested positive controls gilteritinib, quizartinib, and AMG-925. ETH-155008 showed to have highly potent antiproliferative activities against cultured human acute myeloid leukemia cells (MV4-11 and Molm-13) with IC50 at 4.1nM and 12 nM, respectively, and showed remarkable antitumor efficacy in vivo. The in vivo antitumor activity of ETH-155008 was evaluated and compared with midostaurin and gilteritinib in the treatment of the two models with mutant forms in TKD and gatekeeper region, namely BaF3 FLT3-ITD-F691L and BaF3 FLT3-ITD-D835Y, respectively. Treatment with ETH-155008 (40 mg/kg/daily x 18, oral) significantly delayed tumor growth and resulted in a smaller mean tumor size (tumor growth inhibition (TGI) of 86% (p<0.001 compared with the control group) in the BaF3 FLT3-ITD-F691L model, and cured all of the tumor-bearing mice in the BaF3 FLT3-ITD-D835Y model. The antitumor activity of ETH-155008 was comparable to gilteritinib, but much better than midostaurin, the latter showed only mild antitumor activity with ~25% of TGI in the two FLT3 mutant models. We also tested the therapeutic efficacy of ETH-155008 in the human AML xenograft model MV4-11, ETH-155008 cured all of the tumor-bearing mice (mean tumor size at time of treatment 126 mm3), at a dose of 40mg/kg/daily for 14 days, that showed very little toxicity (only 2% body weight loss) which were well below the maximum tolerated dose. ETH-155008 represents a novel dual inhibitor that may yet fulfill the promise of effective AML therapy through dual targeting of FLT3 and CDK4/6. These preclinical results supported the safety and efficacy observed in the preclinical studies and worthy of further clinical evaluation. Disclosures Liu: Euthare LLC: Other: founder. Zhang:shengke therapeutics: Other: cofounder. Yu:shengke Therapeutics: Other: co-founder.

Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines Via an Azo Click-It/Staple-It Approach.

Recent advances in FLT3 inhibitors for acute myeloid leukemia.

Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted Mir-150 Nanoparticles.

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Design, Synthesis, and Evaluation of Pyrido.[3,4-B]pyrazin-2(1h)-one Derivatives As Potent FLT3 Inhibitors

Identification of 2-Aminopyrimidine Derivatives As FLT3 Kinase Inhibitors with High Selectivity over C-Kit.

Discovery of the Selective and Efficacious Inhibitors of FLT3 Mutations

Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia

Discovery of LWY713 As a Potent and Selective FLT3 PROTAC Degrader with in Vivo Activity Against Acute Myeloid Leukemia.

Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.

SKLB-677, an FLT3 and Wnt/β-catenin Signaling Inhibitor, Displays Potent Activity in Models of FLT3-driven AML.

Combining Structure- and Property-Based Optimization to Identify Selective FLT3-ITD Inhibitors with Good Antitumor Efficacy in AML Cell Inoculated Mouse Xenograft Model.

Computer Aided Drug Discovery of Highly Ligand Efficient, Low Molecular Weight Imidazopyridine Analogs As FLT3 Inhibitors.

Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor

Identification of Inhibitors Targeting the FLT3-ITD Mutation Through 4D-QSAR, in Vitro, and in Silico

Discovery of a Highly Selective FLT3 Inhibitor with Specific Proliferation Inhibition Against AML Cells Harboring FLT3-ITD Mutation.

ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia

Design and Synthesis of Selective FLT3 Inhibitors Via Exploration of Back Pocket II

Gaining Selectivity in the Back Pocket of Fms-Like Tyrosine Kinase 3: A Case Study